share_log

HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Lowers Price Target to $2

Benzinga ·  Aug 14, 2023 06:38

HC Wainwright & Co. analyst Yi Chen maintains Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy and lowers the price target from $7 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment